Novavax Plans to Cut $50 Million in Costs, COVID-19 Vaccine Remains Only Marketed Product
None Novavax Incs (NASDAQ: NVAX) CEO, newly appointed CEO John Jacobs, said the company would cut about $50 million in costs in Q1 of 2023 and plans further…
Source: biztoc.com